Different Times Of Treatment Research Articles

Hospitalization During Chemotherapy for Small Cell Lung Cancer

Ninety patients with small cell lung cancer, who received combination chemotherapy, were studied with regard to hospitalization during the treatment period. Chemotherapy was discontinued in case of tumour progression, or, if progression did not occur, after 18 months. The mean hospitalization time was 18 days per patient which constituted 6.7% of the total treatment time in all 90 patients. The hospitalization rate significantly decreased during the first 10 weeks of treatment, and then remained constantly low, with an average hospital time of 3.7 days per patient during maintenance chemotherapy, accounting for 2% of the total maintenance treatment time. Tumour-associated disability was a major purpose for hospital admissions, accounting for 69% of the hospital time during treatment. Except for the first treatment course, which was routinely given in hospital, chemotherapy was administered on an out-patient basis, and only four patients were admitted to hospital to receive maintenance treatment. In these patients, comorbidity and long-distance living may have contributed to the need for hospitalization. Sixteen patients were admitted to hospital at different times of treatment because of treatment complications, mainly severe infections and haemorrhages. It is concluded, that hospitalization rate is a useful and easily understood treatment outcome measure, which, in our study, implied that patients who responded to chemotherapy also gained an improved social mobility in terms of days outside the hospital, although this should not be interpreted as a comprehensive quality of life measure.

Die cytogenetische wirksamkeit des butazolidin R im lymphocytentest in abhängigkeit von der proteinkonzentration des kulturmediums

The cytogenetic action of Butazolidin R in human lymphocyte cultures dependent on the protein concentration of the culture medium . In human lymphocyte cultures from peripheral blood the cytogenetic action of phenylbutazone (PHB, Butazolidin R) was tested. According to the formulation of the question for this investigation, the test method by Moorhead et al. was varied for one of the test series. Independent of the concentration in which it was added to the cultures, the agent induced specific aberrations of the break type and gaps. However, a clear dependence of frequency of aberration on the protein concentration present in the cultures could be ascertained. In cultures with twice the quantity of serum, the frequency of aberration decreased significantly. The mitotic activity after different times of treatment is dependent on the protein concentration as well as on the concentration of PHB. By the frequency of aberration and the mitotic activity after different times of treatment, it is concluded that PHB and the proteins of the serum reciprocate. After 6 h of treatment the greatest possible quantity of PHB seems to be fixed to proteins. The possibilities with respect to this reciprocal action in the application of the lymphocyte test method are discussed.